EUCTR2017-004110-25-DE进行中（未招募）1 期
MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse - PEMAZA
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Signed informed consent
- •- Age =18 years
- •- Patients with NPM1mut AML in complete morphologic remission after conventional chemotherapy (anthracyclines ± cytarabin based)
- •- Detectable measurable residual disease (MRD) indicating imminent hematological relapse (NPM1mut status >1%)
- •- Patients who are not eligible for immediate allogeneic hematopoietic stem cell transplantation
- •- Patients who are not eligible to undergo alternative intensive treatment
- •- Intended AZA therapy for molecular relapse
- •- ECOG performance status of 0 or 1
- •- Adequate organ function as defined by protocol
- •- No allogeneic stem cell transplantation (allo SCT) within 5 years prior to study treatment
- •- Female subject of childbearing potential should have a negative urine or serum pregnancy within 3 days prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
- •- Female subjects of childbearing potential must be willing to use an adequate method of contraception (Section 5.9.2), for the course of the study through 120 days after the last dose of study medication
- •- Male subjects with procreative capacity must agree to use an adequate method of contraception (Section 5.9.2), starting with the first dose of study therapy through 120 days after the last dose of study therapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 14
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 14
排除标准
- •- Current treatment with any investigational drug or within 4 weeks or less than 5 half-lives preceding the first dose of trial medication, whichever is longer
- •- Known hypersensitivity to any of the drugs used or their constituents or to drugs with similar chemical structure
- •- Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment
- •- Known history of active TB (Bacillus Tuberculosis)
- •- Anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier
- •- Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to a previously administered agent
- •Note: Subjects with = Grade 2 neuropathy are an exception to this criterion and may qualify for the study.
- •Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
- •- Completed 24 months of uninterrupted treatment with pembrolizumab or 35 administrations of study medication, whichever is later
- •- Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer
- •- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability
- •- Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
- •- Known history of, or any evidence of active, non-infectious pneumonitis
- •- Severe hepatic impairment (AST and ALT may not exceed three times the normal) or liver cirrhosis or malignant liver tumor
- •- Dialysis dependent renal dysfunction
- •- Known severe congestive heart failure, incidence of clinically unstable cardiac or pulmonary disease
- •- Active infection requiring systemic therapy
- •- History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participat
研究者
相似试验
终止
2 期
MRD-guided Treatment in NPM1mut AML PatientsAcute Myeloid LeukemiaNCT03769532Technische Universität Dresden26
进行中（未招募）
2 期
Pembrolizumab plus chemotherapy for diffuse large B-cell lymphoma that has come back or does not respond to treatmentCancerISRCTN86607306niversity Hospital Southampton NHS Foundation Trust65
招募中
2 期
pembrolizumab plus axitinib trialrenal cell carcinomaJPRN-jRCT1061200062Takehiro Iawata7
进行中（未招募）
1 期
Pembrolizumab and trastuzumab in combination with chemotherapy before and after surgery for patients with HER2-positive gastric cancer - PHERFLOT –HER2 positive, localized esophagogastric adenocarcinomaMedDRA version: 20.1Level: PTClassification code 10062878Term: Gastrooesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10066896Term: HER2 positive gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-006512-87-DEFrankfurter Institut für Klinische Krebsforschung IKF GmbH30
进行中（未招募）
2 期
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic TherapySecondary Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT04284787National Cancer Institute (NCI)60